Research programme: antibody-drug conjugates - LigaChem Biosciences/Ono Pharmaceutical
Latest Information Update: 24 Jan 2025
Price :
$50 *
At a glance
- Originator LigaChem Biosciences; Ono Pharmaceutical
- Developer LigaChem Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer